Revamp Medical

Revamp Medical Overview

Revamp medical was founded with the goal of resolving one of the most urgent unmet needs in Acute Heart Failure patients. The company's product, the DORAYA catheter, deploys temporarily and regulates vascular hemodynamics in acute heart failure patients, including those who have developed diuretic resistance. The Doraya catheter is designed to improve the efficacy of diuretic therapy in patients with acute heart failure (AHF). A manageable flow-reducing Central Venus Catheter, Doraya is deployed in the infrarenal IVC for up to 12 hours, helping cardiologists to temporarily manage venous hemodynamics, central venous pressure, renal afterload, and venous returns. In July 2020, the company's DORAYA acute heart failure catheter received FDA breakthrough device designation.

Cumulative Funding Raised Over Time ($)

Latest News

May 30, 2023 · www.prnewswire.com

growth-positive

Revamp Medical secures Series A Funding to support clinical trials for its Doraya™ catheter for treating heart failure patients

Revamp Medical, Inc. has announced the closing of a Series A preferred stock financing led by KCK Medtech. The financing will support the continued development of Revamps clinical program for Heart Failure congestion management. Revamp Medicals initial product, the Doraya catheter, targets patients in acute Heart Failure and aims to improve hemodynamics, diuresis, and congestion relief. The company is currently recruiting patients for a clinical study. The Doraya catheter is a temporary venous catheter system designed to address unmet needs in the management of Acute Heart Failure. Revamp Medical is headquartered in Israel.

Investment

Jul 14, 2020 · www.massdevice.com

growth-positive

Revamp Medical acute heart failure catheter wins FDA breakthrough device designation

Revamp Medicals Doraya acute heart failure catheter has received FDA breakthrough device designation. The catheter is a temporary intravenous catheter that applies partial adjustable flow for up to 12 hours. The article highlights the medical device and its designation, but does not mention any specific impact on the companys growth. The key theme of the article is the breakthrough device designation for the catheter. The key issues discussed are related to partners and customers. No specific partners or customers are mentioned in the article. The article does not mention any investment or acquisition. The date of the event described in the article is not provided. Confidence level: 8.

PartnersCustomers

Funding

Team Members

3

Employees: 11-50

Web & Social Links

Locations

Mefi St 5, Netanya, Israel

Photos & Videos

1 item(s)

Revamp Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info